Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your not alone buddy. No one is doing well in this market. Selling is constant.
I tried to verify this myself and it was almost impossible to gather a list of presenting companies from 2015. So with that said what other small caps have you heard of presenting at this conference?
Does anyone here find it a little odd that IDRA is presenting at the JP Morgan Conference? Small caps usually have to attend there own conference Biotech Showcase across the street.
Athx issued PR for major catalyst of course it will be up!
Have you looked at the entire biotech sector? If so I believe that explains it all.
I jumped in myself at 2.91 thinking this can't continue to fall. I also was thinking might get some kind of rally before the JP Morgan conference. This selling off has no mercy. I would say bounce but obviously I don't know sh*t. Good luck!
They already cleared it up in the 10k. It amazes me that no one has sought out to contact the SEC. I believe you should.
200 day MA off 30 mins chart or daily? Driving can't check
Can u explain to me what a fluff PR is?
Exactly
Yea it's called advertising there law firm. Happens all the time in bio world.
Really? If it wasn't for Missling raising 10 million then Anavex would not be here today. You need to to some due diligence on CEO payrolls you will find his in line with most.
Excuse me how many degrees do you have again? That's what I thought I will believe and continue to believe in the man who has 12+ years of education post high school. He is a guy that has been there done that. You continue to bash him yet have never walked a day in his shoes.
Question for the board I recently listened to the most recent conference and correct me please if I'm wrong but we are only expecting Orphan Drug status for this month, correct? What other news are we expecting because I heard him say partnership with a prestigious pharma however that isn't expected to be announced this month? Thanks for all the boards help. This is a new position for me and trying to gather as much information as possible.
When we receive "Fast Track Designation" from FDA expect a comment from that guy who writes for the street. You know that f*ing guy right. Adam something. This is his words in regards to a recent question about "Fast Track", (Fast Track releases are "the most oversold and over-hyped announcements that a drug company puts out." He added that the announcements often "exploit" the public's lack of understanding about drug development.) This comment of his came from an interview with cleveland.com.
I suggest to any and everyone who is thinking of selling a single share call Dr. Missling and ask him how he feels about Anavex! Happy Thanksgiving to all and don't forget to be generous and if you can volunteer. There are many people not as fortunate as many of the posters here.
Well ask Dr. Missling if you think that's what's wrong here.
Why do you have a position in this stock? What is your plan for this position (Long, Short, Swing) ? Have a plan execute on the plan and leave emotions out of it. Your watching every tick up and down isn't a very good plan. Your idea of turning off the computer until Dec. 7th sounds like a great idea. I suggest if you have questions speak with Dr. Missling. Good luck!
Yea I don't know fellas!
Message from IR in regards to change in abstracts:
Dear Timothy,
Thank you for your email and continued interest in Anavex Life Sciences Corp. (Nasdaq: AVXL).
There was a typo in the previous version of the abstract.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Christine Payne
Primoris Group Inc.
Toll Free (North America): 1 (866) 505-2895
Outside North America: +1 (416) 489 0092
Fax: +1 (416) 352 5239
ir@anavex.com
The contents of this e-mail are confidential and may be legally privileged. It is intended solely for the addressee. Access to this e-mail by anyone other than the addressee is unauthorized. If you are not the intended recipient (or responsible for delivery of the message to the recipient), you should inform the sender at the e-mail address from which this message was transmitted or call +1 416 489 0092 and delete this message from your system and destroy any hard copies. Unauthorized use, disclosure, copying or distribution is prohibited and may be unlawful.
Email just rec: According to below email from conference manager we will know the results by 2pm. I'm assuming there time?
Dear Timothy,
All poster and oral presentations' abstacts will be available online at 2pm on Saturday, November 7th;
Kind regards,
Benedicte CLEMENT
Conference Manager
So your the next one to be slaughtered huh? Step up to the plate son. This board provides loans to cover shorts margin calls. Unfortunately interest is 100% a day. I'll send you the paperwork?
No it's not I personally tried myself see email below from CTAD conference manager:
Only onsite attendees can have the abstracts.
Once the conference is over, the abstracts will be on the CTAD website.
Best regards,
Benedicte CLEMENT
conference manager
Well that is always a possibility that they had a hand in this nose dive?
I'm not sure how many shares were dumped during that nose dive end of day but it might of been LPC unleashing there shares they received for doing the finance deal?
Response from IR in regards to the deal with Lincoln Financial?
Dear Timothy,
Thank you for your email and continued interest in Anavex Life Sciences Corp.
Anavex is making use of standard customary and housekeeping features available to more mature or NASDAQ-listed companies to have access to capital, which is less costly and less dilutive to existing shareholders.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Christine Payne
Primoris Group Inc.
Toll Free (North America): 1 (866) 505-2895
Outside North America: +1 (416) 489 0092
Fax: +1 (416) 352 5239
Wolf IR return my email about extension of study and said that the ethics committee approved the extension because there were no safety issues so no data was presented for extension.
Do some DD on Lincoln Park and purchase agreements of past with prior companies. I will say that the structure of our deal is extremely important and leads me to believe that this will be used in negotiations more so than a source of capital.
Guys Sal isn't a basher he has flaws like us all. I tend to believe his view that this finance deal could be really bad for Anavex based on prior company dealings with LP. However Missling continues to impress and as it's been said I don't think Misslings financial experience in the market should be taken lightly. His resume is well a thing of beauty. Who am I too say that he should of, would of, could of, done something more beneficial for financing and shareholders. Hell he has made me a ton of dough so until he dissapoints me as a shareholder then he is the best CEO I have come across. I think as shareholders we always want transparency and Missling has done just that. So I will end this with in Missling we trust.
I agree
No they have 5. Recently hired CFO to qualify for Nasdaq
Yea I expect Missling to order Lincoln park purchase shares after our spike from November 7th conference.
Also I wouldn't be surprised to see a few more MM games before Wed because once on Nasdaq the shenanigans that was pulled on Friday will no longer happen to that extent.
Know I understand bro me too. Way to many dissappointments however when I spoke with Missling prior to the July 22 conference I asked him this question in regards to open label trials "with the trials being open label is it fair to say you are aware of data and how the trial progresses after each and every patient." His reply was that is fair to say.
Maybe someone who knows the clinical trial process can answer this for me. I have looked myself on the FDA website but found no definitive answer. After as goes well with our current trial what is next? Can we move to phase III? I believe because we are using a adaptive trial design it is possible to move into phase III, but I'm not certain.
Open label trial! That is all that needs to be said. We will be receiving nothing short of stellar results. After conference I expect the partnership talk to heat up.
You are your info from where about poster presentations? The program which you copied to prior post is comprised of nothing but Oral communications. Poster presentations are observed during coffee breaks and lunch. But who cares as I said I believe Anavex will be presenting something of major significance.
George you are aware that the majority of presentations at this specific conference are oral? However I don't think that it takes away from the significance of Anavex's late breaking oral!
Wolf I emailed this exact question yesterday to IR: copied is below
Sorry Team I forgot to ask this when I sent previous email and this is something that I'm very eager to know. When you applied to the FDA for the extension from 26 weeks to 52 weeks did the FDA want some kind of data supporting your extension? If so what was the data you presented to them if you can answer if you can't please explain why you can't?
No answer as of yet I will update of course the board if I receive a response.
is this some clitch on level II i have 1200 shares purchased at 9.90